Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM45MR0)

Drug Name
HIP-2B Drug Info
Indication
Disease Entry ICD 11 Status REF
Type-1/2 diabetes 5A10-5A11 Phase 1 [1]
Type-2 diabetes 5A11 Phase 1 [2]
Cross-matching ID
TTD Drug ID
DM45MR0

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Regenerating human pro-islet peptide (REG3A) TTL4H8N REG3A_HUMAN Modulator [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Regenerating human pro-islet peptide (REG3A) DTT REG3A 5.755 5.675 5.217 12.045
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Type-1/2 diabetes
ICD Disease Classification 5A10-5A11
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Regenerating human pro-islet peptide (REG3A) DTT REG3A 1.68E-02 -0.13 -0.87
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01933256) Study of Subcutaneous Doses of HIP2B in Subjects With Type 2 Diabetes Mellitus Treated With Metformin. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Hepatocarcinoma-intestine-pancreas/pancreatic associated protein (HIP/PAP) is expressed and secreted by proliferating ductules as well as by hepatocarcinoma and cholangiocarcinoma cells. Am J Pathol.1999 Nov;155(5):1525-33.